MedTrace Logo

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

NCT06197802 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 392

Last updated 2025-07-31

No results posted yet for this study

Summary

This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females 18-26 Years of Age.

Conditions

Interventions

BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)

Three doses administered intramuscularly at 0, 45 day and 6 month.

BIOLOGICAL

Gardasil®9

Three doses administered intramuscularly at 0, 45 day and 6 month.

Sponsors & Collaborators

  • Xiamen Innovax Biotech Co., Ltd

    collaborator INDUSTRY

  • Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

    collaborator INDUSTRY

  • Xiamen University

    lead OTHER

Principal Investigators

  • Jun Zhang, master · Xiamen University

  • Feng-cai Zhu, master · Jiangsu Provincial Centre for Disease Control and Prevention

Eligibility

Min Age
20 Years
Max Age
28 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-30
Primary Completion
2024-04-05
Completion
2025-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06197802 on ClinicalTrials.gov